SFJ Pharma closes transfer of bentracimab assets from PhaseBio
SFJ Pharmaceuticals is claiming victory in its legal dispute with cardiopulmonary diseases focussed US firm PhaseBio Pharmaceuticals (Nasdaq: PHAS) regarding a blood thinner reversal agent, announcing the closing of the sale and transfer of assets related to bentracimab from PhaseBio to SFJ, a California-based drug development company backed by Blackstone Life Sciences and Abingworth.
The sale and transfer was approved on December 31, 2022, by the US Bankruptcy Court for the District of Delaware Chapter 11 case has been pending since October 2022.
Since 2020, SFJ and PhaseBio have worked on co-developing bentracimab (formerly known as PB2452), which has the potential to address a significant unmet need for patients in major bleeding and urgent surgery situations, and SFJ retains deep clinical and commercial expertise related to the bentracimab program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze